Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 191

1.

Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force.

Gauthier S, Alam J, Fillit H, Iwatsubo T, Liu-Seifert H, Sabbagh M, Salloway S, Sampaio C, Sims JR, Sperling B, Sperling R, Welsh-Bohmer KA, Touchon J, Vellas B, Aisen P.

J Prev Alzheimers Dis. 2019;6(3):164-168. doi: 10.14283/jpad.2019.12.

PMID:
31062826
2.

Treatment patterns and burden of behavioral disturbances in patients with dementia in the United States: a claims database analysis.

Aigbogun MS, Stellhorn R, Hartry A, Baker RA, Fillit H.

BMC Neurol. 2019 Feb 28;19(1):33. doi: 10.1186/s12883-019-1260-3.

3.

Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers?

Messner DA, Rabins P, Downing AC, Irizarry M, Foster NL, Al Naber J, Dabbous O, Fillit H, Gabler S, Krakauer R, Lotz D, Payzant E, Schneider L, Tyrone J, Van Amerongen D, Wuest D.

J Prev Alzheimers Dis. 2019;6(1):20-26. doi: 10.14283/jpad.2018.42.

PMID:
30569082
4.

Translating the biology of aging into novel therapeutics for Alzheimer disease.

Hara Y, McKeehan N, Fillit HM.

Neurology. 2019 Jan 8;92(2):84-93. doi: 10.1212/WNL.0000000000006745. Epub 2018 Dec 7. Review.

5.

Accelerating Alzheimer's disease drug innovations from the research pipeline to patients.

Goldman DP, Fillit H, Neumann P.

Alzheimers Dement. 2018 Jun;14(6):833-836. doi: 10.1016/j.jalz.2018.02.007. Epub 2018 Apr 18.

6.

Analysis of Episodes of Care in Medicare Beneficiaries Newly Diagnosed with Alzheimer's Disease.

Khandker RK, Black CM, Xie L, Kariburyo MF, Ambegaonkar BM, Baser O, Yuce H, Fillit H.

J Am Geriatr Soc. 2018 May;66(5):864-870. doi: 10.1111/jgs.15281. Epub 2018 Mar 30.

PMID:
29601083
7.

Getting More Clinically Meaningful Measures of Functional Impairment for Alzheimer's Disease.

Fillit H.

J Prev Alzheimers Dis. 2017;4(2):67-68. doi: 10.14283/jpad.2017.11. No abstract available.

PMID:
29186277
8.

Evaluation of the Neuroprotective Potential of N-Acetylcysteine for Prevention and Treatment of Cognitive Aging and Dementia.

Hara Y, McKeehan N, Dacks PA, Fillit HM.

J Prev Alzheimers Dis. 2017;4(3):201-206. doi: 10.14283/jpad.2017.22. Review.

PMID:
29182711
9.

Alzheimer's Disease-Related Dementias Summit 2016: National research priorities.

Corriveau RA, Koroshetz WJ, Gladman JT, Jeon S, Babcock D, Bennett DA, Carmichael ST, Dickinson SL, Dickson DW, Emr M, Fillit H, Greenberg SM, Hutton ML, Knopman DS, Manly JJ, Marder KS, Moy CS, Phelps CH, Scott PA, Seeley WW, Sieber BA, Silverberg NB, Sutherland ML, Taylor A, Torborg CL, Waddy SP, Gubitz AK, Holtzman DM.

Neurology. 2017 Dec 5;89(23):2381-2391. doi: 10.1212/WNL.0000000000004717. Epub 2017 Nov 8. Review.

10.

Economic Burden, Mortality, and Institutionalization in Patients Newly Diagnosed with Alzheimer's Disease.

Black CM, Fillit H, Xie L, Hu X, Kariburyo MF, Ambegaonkar BM, Baser O, Yuce H, Khandker RK.

J Alzheimers Dis. 2018;61(1):185-193. doi: 10.3233/JAD-170518.

PMID:
29103033
11.

Hospitalizations for ambulatory care sensitive conditions and unplanned readmissions among Medicare beneficiaries with Alzheimer's disease.

Lin PJ, Zhong Y, Fillit HM, Cohen JT, Neumann PJ.

Alzheimers Dement. 2017 Oct;13(10):1174-1178. doi: 10.1016/j.jalz.2017.08.010. Epub 2017 Sep 5.

PMID:
28886338
12.

A Real-world Analysis of Treatment Patterns for Cholinesterase Inhibitors and Memantine among Newly-diagnosed Alzheimer's Disease Patients.

Bent-Ennakhil N, Coste F, Xie L, Aigbogun MS, Wang Y, Kariburyo F, Hartry A, Baser O, Neumann P, Fillit H.

Neurol Ther. 2017 Jun;6(1):131-144. doi: 10.1007/s40120-017-0067-7. Epub 2017 May 15.

13.

Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer's Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data.

Kocis P, Tolar M, Yu J, Sinko W, Ray S, Blennow K, Fillit H, Hey JA.

CNS Drugs. 2017 Jun;31(6):495-509. doi: 10.1007/s40263-017-0434-z.

14.

Letter to the Editor re: Nexus of Cancer & Alzheimer's.

Carrillo MC, Fillit H, Ganguli M, Knopman D, Shineman D, Snyder HM.

Alzheimers Dement. 2017 Jun;13(6):722. doi: 10.1016/j.jalz.2017.03.006. Epub 2017 Apr 19. No abstract available.

PMID:
28431218
15.

Exploring the nexus of Alzheimer's disease and related dementias with cancer and cancer therapies: A convening of the Alzheimer's Association & Alzheimer's Drug Discovery Foundation.

Snyder HM, Ahles T, Calderwood S, Carrillo MC, Chen H, Chang CH, Craft S, De Jager P, Driver JA, Fillit H, Knopman D, Lotze M, Tierney MC, Petanceska S, Saykin A, Seshadri S, Shineman D, Ganguli M.

Alzheimers Dement. 2017 Mar;13(3):267-273. doi: 10.1016/j.jalz.2016.11.002. Epub 2016 Dec 18. Review.

16.

A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline.

Dacks PA, Armstrong JJ, Brannan SK, Carman AJ, Green AM, Kirkman MS, Krakoff LR, Kuller LH, Launer LJ, Lovestone S, Merikle E, Neumann PJ, Rockwood K, Shineman DW, Stefanacci RG, Velentgas P, Viswanathan A, Whitmer RA, Williamson JD, Fillit HM.

Alzheimers Res Ther. 2016 Aug 20;8:33. doi: 10.1186/s13195-016-0200-3. Review.

17.

Medicare Expenditures of Individuals with Alzheimer's Disease and Related Dementias or Mild Cognitive Impairment Before and After Diagnosis.

Lin PJ, Zhong Y, Fillit HM, Chen E, Neumann PJ.

J Am Geriatr Soc. 2016 Aug;64(8):1549-57. doi: 10.1111/jgs.14227. Epub 2016 Jun 13.

PMID:
27295430
18.

Recognizing the Spectrum of Cognitive Impairment to Advance Drug Discovery.

Dacks PA, Fillit HM.

J Am Med Dir Assoc. 2016 May 1;17(5):457-8. doi: 10.1016/j.jamda.2016.02.022. Epub 2016 Mar 9. No abstract available.

PMID:
26969533
19.

An Update on Healthcare Resource Use and Economic Burden In Alzheimer's Disease In The United States (Us) From A Medicare Sample Analysis.

Coste F, Neumann PJ, Xie L, Sanon M, Bent-Ennakhil N, Wang Y, Kariburyo MF, Fillit H.

Value Health. 2015 Nov;18(7):A754. doi: 10.1016/j.jval.2015.09.2924. Epub 2015 Oct 20. No abstract available.

20.

Expert consensus document: Mind the gaps—advancing research into short-term and long-term neuropsychological outcomes of youth sports-related concussions.

Carman AJ, Ferguson R, Cantu R, Comstock RD, Dacks PA, DeKosky ST, Gandy S, Gilbert J, Gilliland C, Gioia G, Giza C, Greicius M, Hainline B, Hayes RL, Hendrix J, Jordan B, Kovach J, Lane RF, Mannix R, Murray T, Seifert T, Shineman DW, Warren E, Wilde E, Willard H, Fillit HM.

Nat Rev Neurol. 2015 Apr;11(4):230-44. doi: 10.1038/nrneurol.2015.30. Epub 2015 Mar 17. Review.

PMID:
25776822
21.

Findings from the National Memory Screening Day program.

Bayley PJ, Kong JY, Mendiondo M, Lazzeroni LC, Borson S, Buschke H, Dean M, Fillit H, Frank L, Schmitt FA, Peschin S, Finkel S, Austen M, Steinberg C, Ashford JW.

J Am Geriatr Soc. 2015 Feb;63(2):309-14. doi: 10.1111/jgs.13234. Epub 2015 Jan 30.

PMID:
25643739
22.

The Road Ahead To Cure And Prevent Alzheimer's Disease: Implementing Prevention into Primary Care.

Fougère B, Vellas B, Delrieu J, Sinclair AJ, Wimo A, Herman CJ, Fillit H, Gauthier S, Oustric S.

J Prev Alzheimers Dis. 2015;2(3):199-211. doi: 10.14283/jpad.2015.73.

PMID:
29226945
23.

Methodological challenges in assessing the impact of comorbidities on costs in Alzheimer's disease clinical trials.

Kahle-Wrobleski K, Fillit H, Kurlander J, Reed C, Belger M.

Eur J Health Econ. 2015 Dec;16(9):995-1004. doi: 10.1007/s10198-014-0648-7. Epub 2014 Nov 20.

24.

Overcoming obstacles to repurposing for neurodegenerative disease.

Shineman DW, Alam J, Anderson M, Black SE, Carman AJ, Cummings JL, Dacks PA, Dudley JT, Frail DE, Green A, Lane RF, Lappin D, Simuni T, Stefanacci RG, Sherer T, Fillit HM.

Ann Clin Transl Neurol. 2014 Jul;1(7):512-8. doi: 10.1002/acn3.76. Epub 2014 Jun 24.

25.

2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease.

Alzheimer's Association National Plan Milestone Workgroup, Fargo KN, Aisen P, Albert M, Au R, Corrada MM, DeKosky S, Drachman D, Fillit H, Gitlin L, Haas M, Herrup K, Kawas C, Khachaturian AS, Khachaturian ZS, Klunk W, Knopman D, Kukull WA, Lamb B, Logsdon RG, Maruff P, Mesulam M, Mobley W, Mohs R, Morgan D, Nixon RA, Paul S, Petersen R, Plassman B, Potter W, Reiman E, Reisberg B, Sano M, Schindler R, Schneider LS, Snyder PJ, Sperling RA, Yaffe K, Bain LJ, Thies WH, Carrillo MC.

Alzheimers Dement. 2014 Oct;10(5 Suppl):S430-52. doi: 10.1016/j.jalz.2014.08.103.

26.

Alzheimer's disease research and development: a call for a new research roadmap.

Feldman HH, Haas M, Gandy S, Schoepp DD, Cross AJ, Mayeux R, Sperling RA, Fillit H, van de Hoef DL, Dougal S, Nye JS; One Mind for Research and the New York Academy of Sciences.

Ann N Y Acad Sci. 2014 Apr;1313:1-16. doi: 10.1111/nyas.12424.

PMID:
24754377
27.

Unintended benefits: the potential economic impact of addressing risk factors to prevent Alzheimer's disease.

Lin PJ, Yang Z, Fillit HM, Cohen JT, Neumann PJ.

Health Aff (Millwood). 2014 Apr;33(4):547-54. doi: 10.1377/hlthaff.2013.1276.

PMID:
24711313
28.

Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer's disease.

Carman AJ, Dacks PA, Lane RF, Shineman DW, Fillit HM.

J Nutr Health Aging. 2014 Apr;18(4):383-92. doi: 10.1007/s12603-014-0021-7. Review.

PMID:
24676319
29.

Dementia Prevention: optimizing the use of observational data for personal, clinical, and public health decision-making.

Dacks PA, Andrieu S, Blacker D, Carman AJ, Green AM, Grodstein F, Henderson VW, James BD, Lane RF, Lau J, Lin PJ, Reeves BC, Shah RC, Vellas B, Yaffe K, Yurko-Mauro K, Shineman DW, Bennett DA, Fillit HM.

J Prev Alzheimers Dis. 2014 Feb;1(2):117-123.

30.

Developing novel blood-based biomarkers for Alzheimer's disease.

Snyder HM, Carrillo MC, Grodstein F, Henriksen K, Jeromin A, Lovestone S, Mielke MM, O'Bryant S, Sarasa M, Sjøgren M, Soares H, Teeling J, Trushina E, Ward M, West T, Bain LJ, Shineman DW, Weiner M, Fillit HM.

Alzheimers Dement. 2014 Jan;10(1):109-14. doi: 10.1016/j.jalz.2013.10.007. Review.

31.

Evidence needs to be translated, whether or not it is complete.

Dacks PA, Bennett DA, Fillit HM.

JAMA Neurol. 2014 Feb;71(2):137-8. doi: 10.1001/jamaneurol.2013.5376. Review. No abstract available.

PMID:
24297103
32.

Progress in novel cognitive enhancers for cognitive aging and Alzheimer's disease.

Shineman DW, Carman AJ, Dacks PA, Lane RF, Fillit HM.

Alzheimers Res Ther. 2013 Oct 2;5(5):45. doi: 10.1186/alzrt209. eCollection 2013.

33.

Optimizing the use of CROs by academia and small companies.

Lane RF, Friedman LG, Keith C, Braithwaite SP, Frearson JA, Lowe DA, Longo FM, Refolo LM, Watterson DM, Tsaioun K, Shineman DW, Fillit HM.

Nat Rev Drug Discov. 2013 Jul;12(7):487-8. doi: 10.1038/nrd4057. No abstract available.

PMID:
23812255
34.

Current evidence for the clinical use of long-chain polyunsaturated n-3 fatty acids to prevent age-related cognitive decline and Alzheimer's disease.

Dacks PA, Shineman DW, Fillit HM.

J Nutr Health Aging. 2013 Mar;17(3):240-51. doi: 10.1007/s12603-012-0431-3.

PMID:
23459977
35.

Improving dementia care: the role of screening and detection of cognitive impairment.

Borson S, Frank L, Bayley PJ, Boustani M, Dean M, Lin PJ, McCarten JR, Morris JC, Salmon DP, Schmitt FA, Stefanacci RG, Mendiondo MS, Peschin S, Hall EJ, Fillit H, Ashford JW.

Alzheimers Dement. 2013 Mar;9(2):151-9. doi: 10.1016/j.jalz.2012.08.008. Epub 2013 Jan 30. Review.

36.
37.

Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer's disease and related disorders.

Lin PJ, Fillit HM, Cohen JT, Neumann PJ.

Alzheimers Dement. 2013 Jan;9(1):30-8. doi: 10.1016/j.jalz.2012.11.002.

PMID:
23305822
38.

The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier).

Boxer AL, Gold M, Huey E, Hu WT, Rosen H, Kramer J, Gao FB, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M, Knopman D, Cairns NJ, Mackenzie IR, Mitic L, Roberson ED, Van Kammen D, Cantillon M, Zahs K, Jackson G, Salloway S, Morris J, Tong G, Feldman H, Fillit H, Dickinson S, Khachaturian ZS, Sutherland M, Abushakra S, Lewcock J, Farese R, Kenet RO, Laferla F, Perrin S, Whitaker S, Honig L, Mesulam MM, Boeve B, Grossman M, Miller BL, Cummings JL.

Alzheimers Dement. 2013 Mar;9(2):189-98. doi: 10.1016/j.jalz.2012.03.003. Epub 2012 Oct 10. Review.

39.

A call for transparent reporting to optimize the predictive value of preclinical research.

Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE, Golub RM, Goudreau JL, Gross RA, Gubitz AK, Hesterlee SE, Howells DW, Huguenard J, Kelner K, Koroshetz W, Krainc D, Lazic SE, Levine MS, Macleod MR, McCall JM, Moxley RT 3rd, Narasimhan K, Noble LJ, Perrin S, Porter JD, Steward O, Unger E, Utz U, Silberberg SD.

Nature. 2012 Oct 11;490(7419):187-91. doi: 10.1038/nature11556.

40.

Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development.

Boxer AL, Gold M, Huey E, Gao FB, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M, Knopman D, Cairns NJ, Mackenzie IR, Mitic L, Roberson ED, Van Kammen D, Cantillon M, Zahs K, Salloway S, Morris J, Tong G, Feldman H, Fillit H, Dickinson S, Khachaturian Z, Sutherland M, Farese R, Miller BL, Cummings J.

Alzheimers Dement. 2013 Mar;9(2):176-88. doi: 10.1016/j.jalz.2012.03.002. Epub 2012 Oct 5. Review.

41.

Beyond amyloid: the future of therapeutics for Alzheimer's disease.

Lane RF, Shineman DW, Steele JW, Lee LB, Fillit HM.

Adv Pharmacol. 2012;64:213-71. doi: 10.1016/B978-0-12-394816-8.00007-6. Review.

PMID:
22840749
42.

Translating current knowledge into dementia prevention.

Román GC, Nash DT, Fillit H.

Alzheimer Dis Assoc Disord. 2012 Oct-Dec;26(4):295-9. doi: 10.1097/WAD.0b013e31825cbc4b. Review.

PMID:
22710935
43.

Clinical trials: new opportunities.

Chapman SB, Cotman CW, Fillit HM, Gallagher M, van Dyck CH.

J Gerontol A Biol Sci Med Sci. 2012 Jun;67(7):773-80. doi: 10.1093/gerona/gls126. Epub 2012 May 8. Review.

44.

Beyond amyloid: a diverse portfolio of novel drug discovery programs for Alzheimer's disease and related dementias.

Lane RF, Shineman DW, Fillit HM.

Alzheimers Res Ther. 2011 Dec 15;3(6):36. doi: 10.1186/alzrt99.

45.

Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies.

Shineman DW, Basi GS, Bizon JL, Colton CA, Greenberg BD, Hollister BA, Lincecum J, Leblanc GG, Lee LB, Luo F, Morgan D, Morse I, Refolo LM, Riddell DR, Scearce-Levie K, Sweeney P, Yrjänheikki J, Fillit HM.

Alzheimers Res Ther. 2011 Sep 28;3(5):28. doi: 10.1186/alzrt90.

46.

An analysis of global research funding for the frontotemporal dementias: 1998-2008.

Walentas CD, Shineman DW, Horton AR, Boeve BF, Fillit HM.

Alzheimers Dement. 2011 Mar;7(2):142-50. doi: 10.1016/j.jalz.2010.11.010. Epub 2011 Jan 26.

PMID:
21276758
48.

Dependence as a unifying construct in defining Alzheimer's disease severity.

McLaughlin T, Feldman H, Fillit H, Sano M, Schmitt F, Aisen P, Leibman C, Mucha L, Ryan JM, Sullivan SD, Spackman DE, Neumann PJ, Cohen J, Stern Y.

Alzheimers Dement. 2010 Nov;6(6):482-93. doi: 10.1016/j.jalz.2009.09.004. Review.

49.

Atorvastatin does not slow cognitive decline in patients with mild to moderate probable Alzheimer's disease who are taking donepezil.

Fillit H.

Evid Based Ment Health. 2010 Nov;13(4):117. doi: 10.1136/ebmh.13.4.117. No abstract available.

PMID:
21036979
50.

Memantine discontinuation and the health status of nursing home residents with Alzheimer's disease.

Fillit H, Hofbauer RK, Setyawan J, Tourkodimitris S, Fridman M, Pejović V, Miller ML, Erder MH, Lyketsos C.

J Am Med Dir Assoc. 2010 Nov;11(9):636-644. doi: 10.1016/j.jamda.2009.12.086. Epub 2010 Aug 21.

PMID:
21029998

Supplemental Content

Loading ...
Support Center